Correvio Pharma Corp. - Ordinary Shares (Canada) (CORV): Price and Financial Metrics
GET POWR RATINGS... FREE!
CORV Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CORV is -39.13 -- better than merely 0.7% of US stocks.
- CORV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.42% of US stocks.
- In terms of volatility of its share price, CORV is more volatile than 98.69% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Correvio Pharma Corp are JE, SPN, AKRX, KODK, and GSKY.
- CORV's SEC filings can be seen here. And to visit Correvio Pharma Corp's official web site, go to www.correvio.com.
CORV Stock Price Chart Interactive Chart >
CORV Price/Volume Stats
|Current price||$0.42||52-week high||$2.79|
|Prev. close||$0.42||52-week low||$0.21|
|Day high||$0.42||Avg. volume||5,353,682|
|50-day MA||$0.39||Dividend yield||N/A|
|200-day MA||$1.10||Market Cap||27.79M|
Correvio Pharma Corp. - Ordinary Shares (Canada) (CORV) Company Bio
Correvio Pharma Corp. (Formerly Cardiome Pharma Corp.), a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. The company was founded in 1986 and is based in Vancouver, Canada.
CORV Latest News Stream
|Loading, please wait...|
CORV Latest Social Stream
View Full CORV Social Stream
Latest CORV News From Around the Web
Below are the latest news stories about Correvio Pharma Corp that investors may wish to consider to help them evaluate CORV as an investment opportunity.
VANCOUVER , May 21, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") pursuant to which ADVANZ PHARMA, through its wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), has agreed to acquire all of the issued and outstanding shares of Correvio for a total purchase price of approximately US$76 million , which includes the repayment of certain Correvio indebtedness, as described in Correvio's information circular dated April 16, 2020 . The Arrangem...
VANCOUVER , May 15, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced the results of voting on matters considered at its annual general and special meeting (the "Meeting") of Correvio shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") which took place in a virtual format earlier today. At the Meeting, Securityholders were asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA").
Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA
VANCOUVER , May 6, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, released a report (the "Glass Lewis Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.
Correvio Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19
Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has postponed the reporting of its financial statements and management discussion and analysis (the "2020 Disclosure") in respect of the first quarter ended March 31, 2020 beyond the previous expected date of May 15, 2020. The Company now expects to release its 2020 Disclosure on or before June 29, 2020, subject to the Company ceasing to be a reporting issuer prior to the filing deadline as a result of the Proposed Arrangement (as defined below).
CORV Price Returns